Tag: Rubius Therapeutics
PBN announces 2020 Best Places to Work honorees
PROVIDENCE – Providence Business News has announced 66 honorees for its 2020 Best Places to Work program.
Each of the companies recognized for this year’s...
Rubius Therapeutics posts $48.5M loss in Q1; prioritizes on oncology and...
CAMBRIDGE, Mass. – Rubius Therapeutics Inc. posted a loss of $48.5 million for the first quarter of 2020, or a loss of 60 cents...
Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and...
PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018.
Loss per diluted share...
Rubius Therapeutics posts $47M loss in Q3 on increase in R&D...
CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company...
Rubius reports $39.4M loss in Q2, heralds progress
PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...
Ocean State starting to see growth in biotech industry
RI BIO, a Providence-based biotechnology trade association, is on a mission to put Rhode Island on the biotech industry’s map. Despite the state having...
Rubius announces 3 new patents for cellular-therapy program
PROVIDENCE – Rubius Therapeutics, a Cambridge, Mass.-based biotech firm that develops and genetically engineers red blood cells for use in medications for rare diseases,...
Rubius Therapeutics reports $32.6M loss in Q1
SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share,...
Rubius appoints Holles to board, Whitehead as SVP, chief quality officer
PROVIDENCE – Rubius Therapeutics Inc. has appointed Natalie Holles to its board of directors and Greg Whitehead as senior vice president and chief quality...
Rubius Therapeutics added to Nasdaq biotechnology index
SMITHFIELD – Biotechnology firm Rubius Therapeutics Inc. was added to the Nasdaq biotechnology index on Dec. 24.
The company, based in Cambridge, Mass., but building...
- Featured Event -
